Rankings
▼
Calendar
UTHR Q3 2016 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena
UTHR
United Therapeutics Corporation
$24B
Q3 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$408M
Gross Profit
$385M
94.2% margin
Operating Income
$239M
58.5% margin
Net Income
$162M
39.6% margin
EPS (Diluted)
$3.50
QoQ Revenue Growth
-1.1%
Cash Flow
Operating Cash Flow
$229M
Free Cash Flow
$220M
Stock-Based Comp.
$50M
Balance Sheet
Total Assets
$2.3B
Total Liabilities
$420M
Stockholders' Equity
$1.8B
Cash & Equivalents
$953M
Revenue Segments
Remodulin
$152M
37%
Tyvaso
$102M
25%
Adcirca
$96M
24%
Orenitram
$41M
10%
Unituxin
$17M
4%
← FY 2016
All Quarters
Q4 2016 →
